Parkure Limited

Product: 
Life Sciences
Status: 
Closed
Sector: 
Parkinsons Research
Aim of funding: 
Seed
HMRC Advance Assurance received: 
Yes

Parkure Limited

Description: 

The Company’s primary intention is the discovery of drugs that can prevent or inhibit the progression of Parkinson’s disease (‘PD’), for which there is currently no cure. Parkure’s primary goal is to discover and co-develop drugs that stop the disease progression; the Company will also exploit any new drugs that lead to the improvement of symptoms.

The Company uses an in-vivo (i.e. in living tissue rather than test tubes) drug discovery platform which seeks to de-risk the downstream drug development process. From this process, the best candidate drugs are then developed as pre-clinically-validated assets which will then be co-developed with a pharmaceutical company partner.

Although there is a significant market for drugs that ameliorate symptoms of PD, there is no treatment currently available that prevents disease progression. Parkure’s disease modifying products will not compete with existing drugs, but will potentially open up a new treatment opportunity as well as a new and potentially larger market.

Opportunity: 

The Company’s focus is pre-clinical. A large number of candidate drug compounds have already been pre-selected based on drug chemistry and ‘targeted pathway’ criteria. A significant portion has already been secured in the form of libraries and more than 1,000 have already been screened with a select few of these drugs showing repeated and significant effects. Those drugs that show a consistent effect in the living system platform are prioritised based on their performance. Based on further testing in an appropriate mouse model and assessment of commercial potential, a number of candidates will be validated at the pre-clinical level. In doing so, it is hoped that the probability of discovering drugs that work and then successfully co-developing them to the market is maximised.

Another key revenue driver is undertaking contracts for the testing of number of compounds for third party pharmaceutical companies using the Company’s unique approach and platform where the compounds are tested in vivo which has a human PD toxic protein expressed in the brain.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.